ArticleEuropean journal of pediatrics2025
Use of milrinone in pediatric intensive care units: a multicenter survey of French-speaking countries.
Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Management of arterial hypotension in critically Ill children: a narrative review and practical approach.Frontiers in pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the practical use of milrinone in French-speaking pediatric intensive care units.
methodsA survey on milrinone therapy use, including indication, dosage, monitoring, weaning and side effects was sent to pediatric intensivists using the e-mail registry of the French-speaking Group of Pediatric Intensive Care and Emergency Medicine Network.
resultsWe received 117 responses from French speaking centers (response rate of 31.2%). We observed a high and widespread use (113/117; 96.6%) of milrinone for several cardiovascular indications [right heart failure with pulmonary arterial hypertension (102/112; 91.1%), cardiogenic shock (90/112; 80.4%), decompensation of chronic heart failure (74/112; 66.1%), postoperative management of cardiac surgery (59/112; 52.7%)], with however highly heterogeneous practices on dosing, therapeutic adjustment, treatment monitoring, and weaning. More than half (60/117; 51.3%) of respondents used milrinone at least once a week. Respondents stated that approximately 25% had no protocol for either initiation or weaning. No maximum duration of treatment was reported. The loading dose was rarely administered.
conclusionsThere are a lack of a clear guidance and recommendations for the use of milrinone in critically ill children despite its frequent and widespread use. Further prospective studies and research are mandatory to improve and tailor milrinone use in critically ill neonates and children. WHAT IS KNOWN: • Milrinone acts as a positive inotropic agent, reduces systemic and pulmonary vascular resistance. • Milrinone is less arrhythmogenic and is associated with lower myocardial oxygen consumption than dobutamine. • The use of milrinone in the postoperative management of pediatric cardiac surgery patients has been extensively studied. WHAT IS NEW: • Widespread use of milrinone in PICUs for several medical indications. • The application of milrinone in pediatric intensive care units demonstrates great heterogeneity. • Further prospective studies are mandatory to improve the use of milrinone in PICUs.
Indexed as
Identifiers
41186722What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.